Hillhouse HCare 2020 Global Healthcare Innovation Summit & Mayo Clinic China Medical Summit – Register Now to Join the Elite Circle!
This August, the global health industry will witness a spotlight moment. The Hillhouse HCare 2020 Global Health Industry Summit & Mayo Clinic China Healthcare Summit will meet you via online live streaming. Academician Wang Chen, Academician Wang Xiaodong, Academician Xie Xiaoliang, Professor Huo Yong, Professor Zhang Wenhong, Moderna... top clinical experts, researchers, policy makers, top investors and entrepreneurs from leading hospitals around the world will gather here to discuss the most cutting-edge industry topics.
Registration for the summit is now open. Spaces are limited; please scan the QR code at the end of the article to register.
Co-hosted by Hillhouse Capital, Mayo Clinic, and Huimei Medical Group, this summit will bring together clinical experts from top hospitals worldwide, innovative drug developers, policymakers, hospital administrators, industry researchers, leading investors, and entrepreneurs to share the most cutting-edge global technologies, exchange advanced practical experiences, and discuss the most pressing challenges facing the healthcare industry today.
The confirmed attendees for this event include a distinguished roster of experts. Among them are Academician Wang Chen, Vice President of the Chinese Academy of Engineering and President of Peking Union Medical College; Dr. Xiaodong Wang, Director of the National Institute of Biological Sciences, Beijing, Foreign Associate of the Chinese Academy of Sciences, and Founder of BeiGene; Dr. Xie X. Sunney, Director of the Beijing Advanced Innovation Center for Genomics at Peking University and Director of the Beijing Future Gene Diagnosis High-Precision Innovation Center, Foreign Associate of the Chinese Academy of Sciences; Professor Huo Yong from Peking University First Hospital and President of the World Chinese Cardiologists Association; Mr. G. Anton Decker, President of Mayo Clinic International; and more than ten other leading experts and academicians in the fields of life sciences and medicine from China and abroad. Also attending will be renowned scholars such as Professor Zhang Wenhong, Director of the Department of Infectious Diseases at Huashan Hospital Affiliated to Fudan University, who has been at the forefront of the fight against the epidemic.
Among them, Academician Wang Chen, a leading expert in respiratory and critical care medicine in China, served as the head of clinical expert groups in Beijing and nationwide during the 2003 SARS outbreak and the 2009 novel influenza A (H1N1) pandemic. He formulated a series of diagnostic and treatment protocols and saved numerous patients on the clinical front lines. During the current COVID-19 pandemic, Academician Wang’s voice has become one of the most closely watched focal points within the medical community.
During the pandemic, Professor Zhang Wenhong won countless followers by explaining complex medical concepts in an accessible yet authoritative manner. Whenever he appeared, he always delivered profound and memorable quotes. It will be intriguing to see what fresh insights Professor Zhang offers in his forward-looking analysis of the epidemic.
This summit focuses on the most cutting-edge and urgent topics in medicine and the pharmaceutical industry. The prevention, control, and treatment of COVID-19 are currently the areas of greatest concern across all sectors, from government and the general public to academia, research institutions, and industry.
Cell therapy is poised to become the most mainstream oncology treatment over the next 30 years; RNA and mRNA therapies focus on continuously expanding into new indications for major diseases; while the diagnosis and treatment of rare diseases center on issues such as R&D costs and market access...
Within the medical and industrial sectors, each of these specialized frontier fields is capable of independently forming a vast ecosystem integrating industry, academia, and research. Global research institutions and corporations are investing hundreds of billions of dollars to achieve breakthroughs and identify optimal solutions within their respective niches. At the Hillhouse HCare 2020 Global Health Industry Summit, you will gain insight into the latest advancements in these cutting-edge areas.
The “Therapeutic Antibodies and Vaccines for COVID-19” sub-forum, specially convened on August 8 at this summit, aims to showcase the remarkable R&D achievements by Chinese enterprises in the field of COVID-19 vaccine development, highlighting diverse approaches that have each yielded distinctive and outstanding results.
This sub-forum featured CEOs from leading Chinese companies developing therapeutic antibodies and vaccines for COVID-19, including Suzhou Abogen Biosciences, Clover Biopharmaceuticals, and Junshi Biosciences, who personally shared their latest R&D advancements. The industrialization progress achieved by these emerging companies represents the highest domestic standards in their respective niche sectors. Furthermore, the international caliber they have demonstrated in the field of vaccines and antibodies serves as a microcosm of the rapid advancements in China’s drug R&D capabilities in recent years.
As a premier global industry summit, this year’s event has attracted heavyweight executives from multinational corporations.
Moderna, the first company globally to successfully develop an mRNA-based COVID-19 vaccine, has gained worldwide recognition for its mRNA-1273 vaccine. Alnylam Pharmaceuticals, another company focused on innovative RNA interference therapies, secured a $2 billion investment from Blackstone’s Life Sciences division in April this year, setting a record in the biopharmaceutical sector. The CEOs of these two companies will share insights on “Opportunities and Challenges in RNA and mRNA Therapies” with attendees. This presents a rare opportunity for Chinese research institutions in this field to engage in valuable exchanges.
In addition, the participation of Juno Therapeutics, a leading company in tumor cell therapy, added significant luster to the summit. Juno was acquired by pharmaceutical giant Celgene for $9 billion in 2018, underscoring its substantial industrial value.
This year’s Hillhouse HCare Global Health Industry Summit will place greater emphasis on the industrial implementation of cutting-edge fields. In addition to addressing topics closely aligned with market concerns, the summit has invited more than ten global innovation leaders and entrepreneurs from the medical and health industries, pioneers in biotechnology, and investors from renowned domestic and international investment institutions. Top-tier professionals from academia, industry, and research are leveraging their shared industry lexicon to build closed-loop ecosystems in various niche sectors, thereby driving these specialized industries toward a clearer and more defined market frontier.
Spanning approximately one week, the conference featured 40 lectures and 16 live broadcasts, covering diverse sectors including healthcare, medical devices, pharmaceutical enterprises, and social security. It fully demonstrated the integration and interaction among industry, academia, research, and clinical practice.
For instance, it is urgent for patients with rare diseases in China to have access to effective and more affordable orphan drugs. The sub-forum titled “Orphan Drug R&D Innovation and Market Access,” scheduled for the morning of August 9, has invited senior executives from companies such as BridgeBio and Argenx. They will engage in comprehensive discussions with Chinese experts on all aspects ranging from research and development to market access and ultimately patient access to medications. Meanwhile, the forum will also focus on the challenges and opportunities encountered by Chinese enterprises engaged in orphan drug R&D, and jointly explore future avenues for collaboration.
Novel formats, fresh perspectives, and a new platform were also prominent highlights of this forum. The Internet has enabled borderless communication. Guided by the vision of fostering industrial integration, international exchange, and economic development, the forum was organized to embody the principle that “connections create opportunities, and opportunities generate value.” Furthermore, the newly built platform incorporated various interactive elements, making all sessions open and engaging. Over the course of five days, you will enjoy a lively and relaxed conference experience while gaining substantial, practical insights.
As the conference’s permanent intellectual property, “HCare” signifies that Hillhouse will harness the power of its platform and leverage its capital advantages to empower the healthcare industry ecosystem. It is committed to addressing the dreams, needs, and aspirations of every scientist, physician, patient, and entrepreneur in the health sector, while fostering the prosperity and vibrant growth of the global healthcare ecosystem.
Scan the QR code to register for the summit now,Note: Mentioning VCBeat in the comments can increase the likelihood of approval during backend review.
